MDS-PB13 Score - Blood based detection of aberrancies by flow cytometry in patients with suspected and confirmed Myelodysplastic Neoplasms
Uta Oelschlaegel(University Hospital Carl Gustav Carus), Malte von Bonin(Städtisches Klinikum Dresden), Jonas Schadt(University Hospital Carl Gustav Carus), Maximilian Alexander Röhnert(University Hospital Carl Gustav Carus), Thomas Krüger(University Hospital Carl Gustav Carus), Leo Ruhnke(Krankenhaus Dresden-Friedrichstadt), Susann Winter(University Hospital Carl Gustav Carus), Frank Kroschinsky(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Uwe Platzbecker(National Center for Tumor Diseases), Katharina Epp(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden)
Cited by 7
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402